Previous studies have demonstrated that less-differentiated T cells are ideal for adoptive T cell transfer therapy ( ACT ) and that fibronectin CH296 ( FN-CH296 ) together with anti-CD3 resulted in cultured cells that contain higher amounts of less-differentiated T cells.
In this phase I clinical trial, researchers build on these prior results by assessing the safety and efficacy of FN-CH296 stimulated T cell therapy in patients with advanced cancer.
Patients underwent fibronectin CH296-stimulated T cell therapy up to six times every two weeks and the safety and antitumor activity of the ACT were assessed. In order to determine immune function, whole blood cytokine levels and the number of peripheral regulatory T cells were analyzed prior to ACT and during the follow up.
Transferred cells contained numerous less-differentiated T cells greatly represented by CD27+CD45RA+ or CD28+CD45RA+ cell, which accounted for approximately 65% and 70% of the total, respectively.
No ACT related severe or unexpected toxicities were observed. The response rate among patients was 22.2% and the disease control rate was 66.7%.
The results obtained in this phase I trial, indicate that FN-CH296 stimulated T cell therapy was very well tolerated with a level of efficacy that is quite promising.
Researchers also surmise that expanding T cell using CH296 is a method that can be applied to other T- cell-based therapies. ( Xagena )
Ishikawa T et al, PLoS One 2014; 9: e83786. doi: 10.1371/journal.pone.0083786. eCollection 2014